Coherus Oncology, Inc. (CHRS) — Stock Score Summary

Coherus Oncology, Inc. (CHRS) has a MoatMap StockRank of 22/100 based on Quality (22/100), Value (37/100), and Momentum (50/100) factor scores. The current signal is SELL. Coherus Oncology is a commercial-stage biopharmaceutical company focused on biosimilars and oncology. It has historically generated significant net losses, lacks a durable economic moat, and operates in highly competitive, price-sensitive markets.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing biosimilar and innovative oncology products. The company's competitive advantage lies in its expertise in navigating complex regulatory pathways for biosimilars, offering cost-effective alternatives to established biologics and strategically expanding its portfolio to address unmet needs in cancer treatment.

Key Financial Metrics

Price$1.42
Market Cap$255M
P/E (Forward)-1.54
Price/Book3.09
Return on Invested Capital-149.5%
Debt/Equity69.16
Gross Margin68.1%
Operating Margin-293.7%
Revenue Growth62.0%
Free Cash Flow$-27M

Coherus Oncology, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Coherus Oncology, Inc.’s (CHRS) StockRank?
MoatMap’s StockRank for Coherus Oncology, Inc. (CHRS) is 22/100, with a Sell signal. It is a composite of Quality (22), Value (37), and Momentum (50) factor ranks across MoatMap’s 19,000+ stock universe.
Does Coherus Oncology, Inc. have an economic moat?
Coherus Oncology, Inc. (CHRS) has a Quality factor score of 22/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Coherus Oncology, Inc. a buy, hold, or sell?
MoatMap’s current signal for Coherus Oncology, Inc. (CHRS) is Sell, based on a StockRank of 22/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Coherus Oncology, Inc. in?
Coherus Oncology, Inc. (CHRS) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksCHRS deep dive reportAI ChampionsHow we score stocksSense-check another stock